Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1998, Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6

Home, 2007, Rosiglitazone RECORD study: glucose control outcomes at 18 months, Diabet Med, 24, 626, 10.1111/j.1464-5491.2007.02160.x

Nauck, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, Diabet Obes Metab, 9, 194, 10.1111/j.1463-1326.2006.00704.x

2005

1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8

Barbier, 2002, Pleiotropic actions of peroxisome proliferator–activated receptors in lipid metabolism and atherosclerosis, Arterioscler Thromb Vasc Biol, 22, 717, 10.1161/01.ATV.0000015598.86369.04

Komajda, 2008, Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study), Cardiovasc Diabetol, 7, 10, 10.1186/1475-2840-7-10

Freed, 2002, Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus, Am J Cardiol, 90, 947, 10.1016/S0002-9149(02)02659-0

Oleksiewicz, 2008, Rat urinary bladder carcinogenesis by dual-acting PPARα+γ agonists, PPAR Res, 2008, 103167, 10.1155/2008/103167

Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9

Home, 2005, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol, Diabetologia, 48, 1726, 10.1007/s00125-005-1869-1

McAfee, 2007, Coronary heart disease outcomes in patients receiving antidiabetic agents, Pharmacoepidemiol Drug Safety, 16, 711, 10.1002/pds.1443

Margolis, 2008, Association between serious ischemic cardiac outcomes and medications used to treat diabetes, Pharmacoepidemiol Drug Safety, 17, 753, 10.1002/pds.1630

Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761

Home, 2007, Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis, N Engl J Med, 357, 28, 10.1056/NEJMoa073394

Kahn, 2008, Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT), Diabetes Care, 31, 845, 10.2337/dc07-2270

Bell, 2004, Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy, Clin Ther, 26, 1714, 10.1016/j.clinthera.2004.10.014

Nesto, 2003, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, Circulation, 108, 2941, 10.1161/01.CIR.0000103683.99399.7E

Dargie, 2007, A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York heart association functional class I or II heart failure, J Am Coll Cardiol, 49, 1696, 10.1016/j.jacc.2006.10.077

Diamond, 2007, Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death, Ann Intern Med, 147, 578, 10.7326/0003-4819-147-8-200710160-00182

Singh, 2007, Rosiglitazone: a meta-analysis, JAMA, 298, 1189, 10.1001/jama.298.10.1189

Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470

Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224

2009